ribociclib plus endocrine therapy in early breast cancer

Release time ：Dec-23,2024

The combination of ribociclib with endocrine therapy may emerge as a potent strategy for the treatment of early-stage breast cancer. By integrating the cyclin-dependent kinase inhibitor ribociclib with conventional endocrine treatments, this therapeutic approach aims to more effectively halt the proliferation of tumor cells. Evidence suggests that for patients with early-stage breast cancer that is hormone receptor-positive and HER2-negative, this combined therapy might offer superior disease-free and overall survival rates compared to endocrine therapy alone.

However, it is important to recognize that the combination of ribociclib and endocrine therapy is not indicated for all early-stage breast cancer patients. The selection of treatment should be tailored to the individual patient's circumstances, taking into account the specific tumor type, stage, overall health status, and potential comorbidities. Furthermore, this treatment may also come with certain side effects, such as fatigue, nausea, and diarrhea, and in severe cases, it could lead to cardiac dysfunction. Consequently, when contemplating the use of ribociclib in conjunction with endocrine therapy, patients should do so under the supervision of a qualified physician, fully informed about the potential risks and benefits of the treatment.

For patients with early-stage breast cancer, timely medical consultation and adherence to professional medical advice are of paramount importance. Throughout the treatment process, patients must strictly adhere to the recommendations provided by their healthcare providers and refrain from altering the treatment plan or medication dosage without guidance. Additionally, regular follow-ups and monitoring are essential to enable timely adjustments to the treatment strategy, ensuring the optimization of therapeutic outcomes.